PRP Under Eye

PRP for Dark Circles Under the Eyes

Dark circles under the eyes are often discussed as though they represent one diagnosis, but the scientific literature describes a more complicated reality. Periorbital hyperpigmentation, often abbreviated as POH, can arise from true pigment, visible vasculature, facial anatomy and shadowing, or a mixture of several factors. This distinction is critical because the same treatment is unlikely to work equally well for every type of under-eye discoloration.

Platelet-rich plasma, or PRP, has attracted interest as a regenerative treatment for the periorbital area because platelets release growth factors, cytokines and immune mediators that may support tissue repair and regeneration. The 2022 source article reviewed the available evidence specifically for periorbital hyperpigmentation and concluded that PRP appears to provide therapeutic benefit in some patients, with relatively limited reported side effects. At the same time, the authors stress that the evidence base remains small and that treatment success may depend strongly on the underlying type of dark circle.

For patients researching PRP for dark circles in Abu Dhabi, the most important message is therefore not simply whether PRP ‘works.’ A more useful question is: what is causing the visible darkness under the eyes, and does that cause match the type of change PRP appears most likely to improve?

What Is Periorbital Hyperpigmentation?

Periorbital hyperpigmentation describes dark discoloration around the eyes, particularly the infraorbital region. Although it is a cosmetic concern rather than a single disease entity, it can have a meaningful psychological and quality-of-life impact. The source article notes that patient-reported Dermatology Life Quality Index data suggest a moderate effect on quality of life.

The visible darkness can be created by multiple mechanisms. Some patients have increased brown pigment. Others have blue or purple discoloration related to visible vessels or vascular congestion. In another group, the skin itself may not be strongly pigmented at all; instead, facial structure and the tear trough produce a shadow. Many patients have a mixed pattern.

This is why treatment based only on a photograph or on the word ‘dark circles’ can be misleading. The treatment target must match the dominant mechanism.

How Can True Pigmentation Be Distinguished from Tear-Trough Shadowing?

The source article highlights a simple clinical concept: manual stretching of the skin can help distinguish true hyperpigmentation from shadowing related to the tear trough. If the apparent darkness becomes lighter when the under-eye skin is stretched, that finding suggests a structural or tear-trough component rather than pure pigment alone.

This does not replace a medical assessment, but it illustrates the underlying principle. A treatment intended to change skin biology may not correct a shadow caused by anatomy. Conversely, a volumizing treatment may not be the right solution for a patient whose dominant concern is true brown pigmentation.

A careful assessment should therefore focus on colour, depth, contour, visible vascularity, oedema and whether the apparent darkness changes with stretching or lighting.

What Is PRP and Why Is It Used Under the Eyes?

Platelet-rich plasma is prepared from a patient’s own blood and contains a concentrated platelet fraction. The rationale described in the source article is regenerative: activated platelets release growth factors, cytokines and immune mediators that may initiate tissue repair and regeneration at the injection site.

In the context of periorbital hyperpigmentation, the proposed benefit is not simply ‘adding volume.’ The article discusses histological findings showing increased collagen and elastic fibres at PRP injection sites. This has led to the hypothesis that PRP may thicken the superficial dermis and reduce the visibility of underlying vessels, which could help explain why vascular-type POH may respond better than a purely pigmented type.

This mechanism is biologically plausible, but the source also makes clear that the clinical evidence is still limited. PRP should therefore be described as a treatment with encouraging but incomplete evidence rather than a definitive solution for every form of dark circles.

What Does the Published Clinical Evidence Show?

The source article states that only a few clinical studies with small sample sizes had evaluated PRP for periorbital hyperpigmentation during the preceding decade. Despite this limitation, repeated PRP sessions generally showed both physician-reported and patient-reported improvement.

The most detailed result summarized in the letter involved 50 patients with Fitzpatrick skin types III to V who received three PRP sessions one month apart. After three sessions, dermatologists rated 50% of patients as having moderate improvement, 12% as having significant improvement and 6% as having excellent improvement.

Patient satisfaction was also reported. Using the four-point scale described by the authors, 72% of patients gave a score of 2 or greater. These results are clinically encouraging, but they should be interpreted cautiously because the study was relatively small and the outcome categories were subjective.

The reported outcomes do not mean that 68% of all future patients will achieve a specific result. They come from one small published study in a selected population with Fitzpatrick skin types III-V. The source article itself emphasizes the limited number and size of available studies.

Does PRP Work Better for Vascular or Pigmented Dark Circles?

One of the most clinically useful observations in the source is that PRP may not perform equally across all types of POH. The article notes that vascular-type periorbital hyperpigmentation appeared to respond better to PRP than pigmented-type POH in the available evidence.

This difference is consistent with the histological observation of increased collagen and elastic fibres after PRP. If the superficial dermis becomes thicker or structurally improved, underlying blue or purple vascular colour may become less visible. By contrast, a patient with predominantly brown pigment may require treatment directed more specifically at pigmentation.

This does not mean that PRP has no role in pigmented cases. Rather, it means that the expected response should be individualized and that the dominant type of discoloration should be identified before treatment.

PRP vs Carboxytherapy for Periorbital Hyperpigmentation

The source article cites a study comparing PRP with carboxytherapy for periocular hyperpigmentation and reports that no clinical difference was found between the two approaches. That finding is useful because it prevents overstating PRP as automatically superior to other treatments.

For a patient, the practical implication is that the choice between modalities should not be based only on popularity. It should consider the type of dark circle, the clinician’s experience, the treatment goals and the available evidence.

Because the uploaded source does not provide detailed comparative procedural protocols, costs, downtime schedules or long-term superiority data, this website content should not make claims in those areas.

Does the Way PRP Is Prepared Change the Result?

A major limitation in PRP research is the lack of standardization. Different studies use different preparation systems, centrifugation methods and activation techniques. The source article specifically discusses a comparison between a double-spin method using calcium chloride for platelet activation and a single-spin method using low temperature for activation.

In that evidence, no significant difference in treatment success was identified between the two preparation and activation approaches. The authors therefore suggest that the exact preparation method may not be the main determinant of efficacy, although they also state that further research is necessary.

This should not be interpreted as proof that all PRP systems are equivalent. It means only that within the limited comparative evidence summarized in this letter, the two specific preparation strategies did not show a significant difference in clinical success.

How Many PRP Sessions Are Supported by the Source?

The main clinical study summarized in the source used three PRP sessions performed one month apart. That protocol is useful as an example of how PRP was studied, but it should not be presented as a universal prescription for every patient.

The source article does not establish an optimal number of sessions, maintenance schedule or standardized injection protocol. Because PRP preparation and treatment methods remain heterogeneous across the literature, a clinic website should avoid implying that one fixed protocol has been proven to be superior.

Any treatment schedule should therefore be described as clinician-dependent and patient-specific rather than as an evidence-mandated formula.

What Side Effects Were Reported?

The source article characterizes PRP as having a favourable side-effect profile in the available reports. The main adverse effect mentioned is mild-to-moderate pain, which rarely persists.

The letter does not provide a comprehensive adverse-event registry, nor does it quantify uncommon complications. Because the published studies were small, absence of frequently reported serious events should not be confused with proof that no serious event can ever occur.

Who May Be a More Suitable Candidate for PRP?

The source does not provide a formal eligibility checklist, but its central argument allows a cautious clinical framework. Patients whose under-eye darkness has a vascular component may be more likely to benefit than patients with predominantly pigmented POH. Patients with purely structural shadowing may require correction of the anatomical cause rather than relying on PRP alone.

A reasonable source-based assessment therefore focuses first on classification: Is the darkness brown, blue-purple, shadow-based or mixed? Is oedema present? Does stretching change the appearance? Is the problem primarily a skin-colour issue or an anatomical contour issue?

The correct treatment cannot be selected by the label ‘dark circles’ alone.

When PRP May Not Address the Main Problem

• Predominantly structural shadowing from a tear trough: the source emphasizes distinguishing this from true hyperpigmentation.
• Predominantly pigmented brown POH: the available evidence discussed suggests a weaker response to PRP than vascular-type POH.
• Mixed POH : A single modality may not address every contributing component.
• Patients expecting guaranteed or dramatic improvement: the evidence base is small and outcomes vary.
• Situations where a different modality is required to address the dominant cause: the source supports classification-driven treatment selection rather than universal PRP use.

A Stepwise Assessment Framework

1. Identify whether the visible darkness is primarily pigmented, vascular, structural or mixed.
2. Assess whether manual stretching reduces the apparent darkness, which may suggest a tear-trough or shadow component.
3. Look for blue-purple vascular show-through and associated oedema.
4. Consider whether the patient’s main concern is discoloration, shadowing, skin quality or a combination.
5. Explain that PRP evidence is encouraging but based on a small number of studies.
6. Set expectations around variable improvement rather than guaranteed clearing of dark circles.
7. If PRP is selected, document baseline appearance so changes can be assessed consistently.

Why Diagnosis Matters More Than Marketing Labels

Many aesthetic treatments are marketed using broad terms such as ‘under-eye rejuvenation’ or ‘dark circle treatment.’ The source article argues for a more precise approach. Periorbital hyperpigmentation is not one uniform entity, and treatment choice should follow etiology.

This is especially important because a brown pigmented problem, a blue vascular problem and a tear-trough shadow can look similar to a patient in the mirror. If these are treated as though they are interchangeable, even a technically well-performed treatment may produce disappointing results.

A scientifically stronger clinic message is therefore: classify first, then treat.

Limitations of the Current PRP Evidence

The source is very clear that PRP research for periorbital hyperpigmentation is limited. Only a few studies with small samples had been conducted, and there was no standardization of PRP preparation and activation. These limitations make it difficult to define a single best protocol or to predict exactly which patient will achieve a specific degree of improvement.

• Small study populations.
• Few clinical studies specifically focused on POH.
• Variable PRP preparation and activation methods.
• Subjective physician- and patient-reported outcome measures.
• Limited evidence comparing PRP directly with other therapies.
• Uncertainty regarding the optimal treatment protocol and long-term durability.

These gaps do not mean PRP is ineffective. They mean that claims should be proportional to the strength of evidence. The most defensible conclusion from the uploaded article is that PRP appears to have therapeutic benefit with limited reported side effects, while POH subtype may be especially important in selecting suitable patients.